TORONTO, Sept. 25, 2013 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the Japanese transcatheter embolization and occlusion (TEO) device market will expand as a number of new products enter the market through 2021. The embolization particle segment will witness the most market activity and fastest growth as a result of numerous product approvals and significant merger and acquisition activity.
"Traditionally, gelatin sponge particles were the only embolization particles available for TEO procedures in Japan," said MRG Analyst Michelle Chan. "Over the next few years, the entry of drug-eluting beads (DEBs), microspheres and radioembolization spheres will cause substantial market growth because these products will allow for novel ways to perform transcatheter arterial chemoembolization, especially in complex cases where gelatin sponge particles are ineffective."
For example, the newer embolization particles can be used for more targeted treatment of liver cancer, which is highly prevalent in Japan. These novel products, as opposed to traditional treatment methods, can also be used in patients with deteriorated liver function. As a result, DEBs, microspheres and radioembolization spheres will be adopted rapidly despite their premium price.
Competitive dynamics are also constantly changing in the embolization particle market. In addition to the entrance of new competitors, acquisitions have become more common. A recent example is BTG's acquisition of Nordion's TheraSphere radioembolization sphere product, a move that will further diversify its embolization particle offerings, which also include DEB and microsphere products. Distributor relationships will also be a key to success in this market going forward; BTG will likely continue to partner with Eisai in Japan, while strong competitor Merit Medical Systems will sell its products through Nippon Kayaku, the leader of the gelatin sponge particle market in Japan.
Overall, the considerable expansion of the embolization particle segment and increasing Japanese physician adoption of endovascular techniques will ultimately combat the negative effects of biennial reimbursement cuts in Japan, allowing TEO device revenues in the country to approach $500 million by 2021.
Millennium Research Group's Japanese Markets for Transcatheter Embolization and Occlusion Devices 2013 report includes unit, procedure, average selling price and revenue information, along with market drivers and limiters and a competitive landscape for interventional neuroradiology (INR) embolization coils, INR coiling-assist devices, INR flow-diverting devices, peripheral vascular (PV) embolization coils, PV plugs, embolization particles, liquid embolics and TEO accessory devices in Japan.
About Millennium Research Group Millennium Research Group (www.MRG.net), a Decision Resources Group company (www.DecisionResourcesGroup.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.
About Decision Resources Group Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders